Cargando…
Cancer Chemoprevention Volume 2: Strategies for Cancer Chemoprevention /
Much progress has been made in discovering and developing agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. In Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, leading chemopreventives investigators c...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Totowa, NJ :
Humana Press : Imprint: Humana,
2005.
|
| Edición: | 1st ed. 2005. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-1-59259-768-0 | ||
| 003 | DE-He213 | ||
| 005 | 20220116060000.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2005 xxu| s |||| 0|eng d | ||
| 020 | |a 9781592597680 |9 978-1-59259-768-0 | ||
| 024 | 7 | |a 10.1007/978-1-59259-768-0 |2 doi | |
| 050 | 4 | |a RC254-282 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Cancer Chemoprevention |h [electronic resource] : |b Volume 2: Strategies for Cancer Chemoprevention / |c edited by Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman. |
| 250 | |a 1st ed. 2005. | ||
| 264 | 1 | |a Totowa, NJ : |b Humana Press : |b Imprint: Humana, |c 2005. | |
| 300 | |a XXI, 543 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 505 | 0 | |a Chemopreventive Agent Development Science -- Characterization of Natural Product Chemopreventive Agents -- Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs -- Potential Use of Transgenic Mice in Chemoprevention Studies -- Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies -- Pathology of Incipient Neoplasia -- Quantitative Nuclear Grade -- Enabling Discovery Through Online Cancer Genome Databases and Analytic Tools -- Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention -- Clinical Applications of Proteomics -- Bioinformatics and Whole-Genome Technologies -- Models of Absolute Risk -- Genetic Polymorphisms and Risk Assessment for Cancer Chemoprevention -- Design Issues in Prostate Cancer Chemoprevention Trials -- Recruitment Strategies for Cancer Prevention Trials -- Cancer Chemoprevention at Major Cancer Target Sites -- Prostate Cancer Prevention -- Use of PSA to Evaluate Risk and Progression of Prostate Cancer -- Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs -- Ductal Lavage -- Counteracting Estrogen as Breast Cancer Prevention -- Chemoprevention of Colorectal Cancer -- Screening in Risk Evaluation and Prevention of Colorectal Cancer -- Strategies in Lung Cancer Chemoprevention -- Lung Cancer Chemoprevention -- Bladder Cancer -- Barrett's Esophagus -- Endoscopic Detection of Esophageal Neoplasia -- Chemoprevention Strategies for Esophageal Squamous Cell Carcinoma -- Chemoprevention of Upper Aerodigestive Tract Cancer -- Chemoprevention of Oral Cancer -- Strategies in Skin Cancer Chemoprevention -- Opportunities and Challenges for Skin Cancer Chemoprevention -- Progress in Developing Effective Chemoprevention Agents for Cervical Neoplasia -- Immunoprevention of Cervical Cancer -- Objective Biomarkers in Endometrioid-Type Endometrial Carcinogenesis -- Epithelial Ovarian Cancer -- Strategies for Chemoprevention in Pancreatic Cancer -- Clinical Strategies for Chemoprevention of Liver Cancer -- Chemoprevention. | |
| 520 | |a Much progress has been made in discovering and developing agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. In Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention, leading chemopreventives investigators comprehensively describe the exciting methodologies that are accelerating progress in the chemoprevention field and review the state of clinical development of preventive agents in the major human cancer target organs. The authors provide sound guidelines for cancer chemopreventive drug development, detailing general strategies and methods for drug discovery, preclinical efficacy, characterization of precancers, safety evaluation of clinical cohorts, and clinical trial design. Additional chapters address strategies for and the status of chemopreventive agent development in multiple myeloma and cancers of the prostate, breast, lung, colon, bladder, head and neck, esophagus, pancreas, ovary, endometrium, cervix, skin, and liver. The emphasis is on documenting the characterization and application of reliable biomarkers during chemopreventive drug development. Highlights include an elegant approach to identifying chemopreventive agents in natural products, the development of preclinical models for evaluating potential chemopreventive agents, the genomics and proteomics of potential applications, and approaches for determining which populations will likely benefit from chemopreventive intervention. A companion volume, Promising Cancer Chemopreventive Agents, comprehensively surveys those agents that have promise, or have already been successfully used, to treat precancerous conditions or inhibit carcinogenesis. A value-added compact disk containing a companion ebook version of Cancer Chemoprevention, Volume 2: Strategies for Cancer Chemoprevention is included for downloading and use in the reader's PC or PDA. Up-to-date and highly practical, Cancer Chemoprevention, Volumes 1 & 2, offer oncologists, pharmacologists, medicinal chemists, and toxicologists a comprehensive reference survey on the identification of those promising cancer chemopreventive agents that will help stimulate further research and the development of novel approvable drugs. | ||
| 650 | 0 | |a Oncology. | |
| 650 | 1 | 4 | |a Oncology. |
| 700 | 1 | |a Kelloff, Gary J. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Hawk, Ernest T. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Sigman, Caroline C. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9781588290779 |
| 776 | 0 | 8 | |i Printed edition: |z 9781627038171 |
| 830 | 0 | |a Cancer Drug Discovery and Development, |x 2196-9914 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-1-59259-768-0 |z Texto Completo |
| 912 | |a ZDB-2-SME | ||
| 912 | |a ZDB-2-SXM | ||
| 950 | |a Medicine (SpringerNature-11650) | ||
| 950 | |a Medicine (R0) (SpringerNature-43714) | ||